slt

Suki Shergill

Executive Vice President, Global Pricing & Market Access

Experience and Expertise

Suki maintains a clear commercial focus informed by wide-ranging local and international market experience. She leverages her extensive line and matrix management background in successfully leading organizations through change.

 

Since joining Sirtex in 2015, Suki has applied her deep knowledge of pricing, market access and health economics, along with innovative methods, to achieve measurable results. Her accomplishments have included building a strong Reimbursement and Market Access team and helping to assess new-market expansion by providing comprehensive insights on countries' healthcare systems and the impact of international price referencing.

 

Prior to Sirtex, Suki spent four years at Allergan, where she progressed from Senior Manager of HEPRA Ophthalmology for the EMEA Region to Director/Head of Ophthalmology. Before that, she advanced through four levels of promotion in just over eight years at Eli Lilly, culminating in the role of UK Payer Transformation Strategy Consultant, Sales and Marketing.

 

Suki holds a Master of Business Administration in Marketing from the Aston University Business School, a Master of Science in Clinical Pharmacy from Nottingham University and a Bachelor of Science in Pharmacy (with honors) from Liverpool University. She passed her ABPI exam with distinction in 2005.




slt
Kevin R. Smith
CEO

slt
Paul Andreassi
Executive Vice President of Global Quality Assurance

slt
Jesse Hansen
Global Head of Marketing

slt
Francis Jannot
Executive Vice President of International Sales

slt
Cathleen Lowndes
Chief Human Resources Officer

slt
Amy Pan
Chief Financial Officer

slt
Suki Shergill
Executive Vice President, Global Pricing & Market Access

slt
Kevin P. Smith
General Counsel & Executive Vice President, Business Development

slt
Grant Spindler
Global Head of Operations

slt
MaryLou Stroumbos
Executive Vice President, Regulatory Affairs

slt
Mark Turco
Global Chief Medical Officer & Executive Vice President of Research & Development



Now leaving sirtex.com

You are about to leave the Sirtex Web site. This link is provided to you as a service and will take you to a site maintained by a third party who is solely responsible for the content.

Please be aware that Sirtex takes no responsibility for content of these external sites, nor do we endorse, warrant or guarantee the products, services or information described or offered on other internet sites.

Click 'Continue' to proceed to the third-party Web site.

Continue

×

Now leaving sirtex.com

You are about to leave the Sirtex Website. This link is provided to you as a service and will take you to the Sirtex Virtual Booth.

Sirtex is responsible for the content of the Virtual Booth, which is hosted on a website maintained by a third-party. Except for Sirtex’s Virtual Booth experience, please be aware that Sirtex takes no responsibility for the other content of these external sites, nor do we endorse, warrant, or guarantee the products, services or information described or offered on other internet sites.

Continue

×

You are now leaving your current sirtex.com region

The Sirtex site you are linking to is intended only for healthcare practitioners and patients outside your current region. Any products discussed herein may have different approved product labeling; therefore, any information provided may not be appropriate for use in your region.

Click 'Continue' to proceed to the other Sirtex region Web site.

Continue

×

Effective May 7, 2021, SIR-Spheres will have the following indication for use:
SIR-Spheres Y-90 resin microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC) and unresectable metastatic liver tumors from primary colorectal cancer in patients refractory to or intolerant of chemotherapy.

Click here to view our Technical Bulletin.

Ok